| Year |
Citation |
Score |
| 2024 |
Mahmood N, Arakelian A, Szyf M, Rabbani SA. Methyl-CpG binding domain protein 2 (Mbd2) drives breast cancer progression through the modulation of epithelial-to-mesenchymal transition. Experimental & Molecular Medicine. PMID 38556549 DOI: 10.1038/s12276-024-01205-2 |
0.456 |
|
| 2022 |
Mehdi A, Attias M, Arakelian A, Piccirillo CA, Szyf M, Rabbani SA. Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone. Cancers. 15. PMID 36612044 DOI: 10.3390/cancers15010048 |
0.421 |
|
| 2021 |
Mehdi A, Rabbani SA. Role of Methylation in Pro- and Anti-Cancer Immunity. Cancers. 13. PMID 33535484 DOI: 10.3390/cancers13030545 |
0.327 |
|
| 2020 |
Mahmood N, Arakelian A, Muller WJ, Szyf M, Rabbani SA. An enhanced chemopreventive effect of methyl donor S-adenosylmethionine in combination with 25-hydroxyvitamin D in blocking mammary tumor growth and metastasis. Bone Research. 8: 28. PMID 34290227 DOI: 10.1038/s41413-020-0103-6 |
0.439 |
|
| 2020 |
Mahmood N, Arakelian A, Khan HA, Tanvir I, Mazar AP, Rabbani SA. uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions. Bone Research. 8: 18. PMID 33863872 DOI: 10.1038/s41413-020-0094-3 |
0.462 |
|
| 2020 |
Mahmood N, Arakelian A, Cheishvili D, Szyf M, Rabbani SA. S-adenosylmethionine in combination with decitabine shows enhanced anti-cancer effects in repressing breast cancer growth and metastasis. Journal of Cellular and Molecular Medicine. PMID 32720467 DOI: 10.1111/Jcmm.15642 |
0.485 |
|
| 2020 |
Mahmood N, Arakelian A, Muller WJ, Szyf M, Rabbani SA. An enhanced chemopreventive effect of methyl donor S-adenosylmethionine in combination with 25-hydroxyvitamin D in blocking mammary tumor growth and metastasis. Bone Research. 8: 28. PMID 32714613 DOI: 10.1038/S41413-020-0103-6 |
0.526 |
|
| 2020 |
Mehdi A, Cheishvili D, Arakelian A, Bismar TA, Szyf M, Rabbani SA. DNA methylation signatures of Prostate Cancer in peripheral T-cells. Bmc Cancer. 20: 588. PMID 32576165 DOI: 10.1186/S12885-020-07078-8 |
0.424 |
|
| 2020 |
Mahmood N, Arakelian A, Khan HA, Tanvir I, Mazar AP, Rabbani SA. uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions. Bone Research. 8: 18. PMID 32337090 DOI: 10.1038/S41413-020-0094-3 |
0.545 |
|
| 2020 |
Mehdi A, Attias M, Mahmood N, Arakelian A, Mihalcioiu C, Piccirillo CA, Szyf M, Rabbani SA. Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma Frontiers in Oncology. 10. DOI: 10.3389/Fonc.2020.01361 |
0.39 |
|
| 2019 |
Mahmood N, Rabbani SA. Targeting DNA Hypomethylation in Malignancy by Epigenetic Therapies. Advances in Experimental Medicine and Biology. 1164: 179-196. PMID 31576549 DOI: 10.1007/978-3-030-22254-3_14 |
0.355 |
|
| 2019 |
Mahmood N, Rabbani SA. DNA Methylation Readers and Cancer: Mechanistic and Therapeutic Applications. Frontiers in Oncology. 9: 489. PMID 31245293 DOI: 10.3389/Fonc.2019.00489 |
0.354 |
|
| 2018 |
Parashar S, Cheishvili D, Mahmood N, Arakelian A, Tanvir I, Khan HA, Kremer R, Mihalcioiu C, Szyf M, Rabbani SA. DNA methylation signatures of breast cancer in peripheral T-cells. Bmc Cancer. 18: 574. PMID 29776342 DOI: 10.1186/s12885-018-4482-7 |
0.329 |
|
| 2018 |
Mahmood N, Mihalcioiu C, Rabbani SA. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. Frontiers in Oncology. 8: 24. PMID 29484286 DOI: 10.3389/Fonc.2018.00024 |
0.401 |
|
| 2018 |
Mahmood N, Cheishvili D, Arakelian A, Tanvir I, Khan HA, Pépin AS, Szyf M, Rabbani SA. Methyl donor S-adenosylmethionine (SAM) supplementation attenuates breast cancer growth, invasion, and metastasis in vivo; therapeutic and chemopreventive applications. Oncotarget. 9: 5169-5183. PMID 29435170 DOI: 10.18632/Oncotarget.23704 |
0.562 |
|
| 2018 |
Mahmood N, Cheishvili D, Arakelian A, Muller WJ, Tanveer I, Khan H, Szyf M, Rabbani SA. Abstract A09: Development of epigenetic-based strategies for blocking breast cancer growth, invasion, and metastasis in vitro and in vivo Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Tcm17-A09 |
0.588 |
|
| 2018 |
Mahmood N, Arakelian A, Muller WJ, Szyf M, Rabbani SA. Abstract 1388: Pharmacologic targeting of DNA methylation blocks breast cancer growth and metastasis Cancer Research. 78: 1388-1388. DOI: 10.1158/1538-7445.Am2018-1388 |
0.574 |
|
| 2017 |
Dai M, Al-Odaini AA, Fils-Aimé N, Villatoro MA, Guo J, Arakelian A, Rabbani SA, Ali S, Lebrun JJ. Erratum to: Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion. Breast Cancer Research : Bcr. 19: 43. PMID 28351372 DOI: 10.1186/s13058-017-0831-8 |
0.401 |
|
| 2017 |
Mahmood N, Cheishvili D, Arakelian A, Muller WJ, Szyf M, Rabbani SA. Abstract 4346: S-Adenosyl methionine (SAM) blocks breast cancer growth, invasion and metastasisin vitroandin vivo Cancer Research. 77: 4346-4346. DOI: 10.1158/1538-7445.Am2017-4346 |
0.435 |
|
| 2015 |
Cheishvili D, Stefanska B, Yi C, Chen Li C, Yu P, Arakelian A, Tanvir I, Ahmed Khan H, Rabbani S, Szyf M. A common promoter hypomethylation signature in invasive breast, liver and prostate cancer cell lines reveals novel targets involved in cancer invasiveness. Oncotarget. PMID 26427334 DOI: 10.18632/Oncotarget.5291 |
0.526 |
|
| 2015 |
Shukeir N, Stefanska B, Parashar S, Chik F, Arakelian A, Szyf M, Rabbani SA. Pharmacological methyl group donors block skeletal metastasis in vitro and in vivo. British Journal of Pharmacology. 172: 2769-81. PMID 25631332 DOI: 10.1111/Bph.13102 |
0.397 |
|
| 2015 |
Parashar S, Cheishvili D, Arakelian A, Hussain Z, Tanvir I, Khan HA, Szyf M, Rabbani SA. S-adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: therapeutic and diagnostic clinical applications. Cancer Medicine. 4: 732-44. PMID 25619880 DOI: 10.1002/Cam4.386 |
0.5 |
|
| 2015 |
Cheishvili D, Stefanska B, Yi C, Li CC, Yu P, Arakelian A, Tanvir I, Khan HA, Rabbani S, Szyf M. A common promoter hypomethylation signature in invasive breast, liver and prostate cancer cell lines reveals novel targets involved in cancer invasiveness Oncotarget. 6: 33253-33268. DOI: 10.18632/oncotarget.5291 |
0.455 |
|
| 2014 |
Cheishvili D, Chik F, Li CC, Bhattacharya B, Suderman M, Arakelian A, Hallett M, Rabbani SA, Szyf M. Synergistic effects of combined DNA methyltransferase inhibition and MBD2 depletion on breast cancer cells; MBD2 depletion blocks 5-aza-2'-deoxycytidine-triggered invasiveness. Carcinogenesis. 35: 2436-46. PMID 25178277 DOI: 10.1093/Carcin/Bgu181 |
0.533 |
|
| 2014 |
Stefanska B, Cheishvili D, Suderman M, Arakelian A, Huang J, Hallett M, Han ZG, Al-Mahtab M, Akbar SM, Khan WA, Raqib R, Tanvir I, Khan HA, Rabbani SA, Szyf M. Genome-wide study of hypomethylated and induced genes in patients with liver cancer unravels novel anticancer targets. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3118-32. PMID 24763612 DOI: 10.1158/1078-0432.Ccr-13-0283 |
0.354 |
|
| 2013 |
Rabbani SA, Arakelian A, Farookhi R. LRP5 knockdown: effect on prostate cancer invasion growth and skeletal metastasis in vitro and in vivo. Cancer Medicine. 2: 625-35. PMID 24403228 DOI: 10.1002/Cam4.111 |
0.496 |
|
| 2013 |
Dai M, Al-Odaini AA, Fils-Aimé N, Villatoro MA, Guo J, Arakelian A, Rabbani SA, Ali S, Lebrun J. Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion. Breast Cancer Research : Bcr. 15: R49. PMID 23786849 DOI: 10.1186/Bcr3441 |
0.525 |
|
| 2013 |
Kandela I, Ugolkov A, Francia G, Rabbani S, Kerbel RS, Mazar AP. Abstract 863: Inhibition of breast cancer metastaticprogression by a novel uPAR targeted monoclonal antibody, ATN-658, correlateswith the uPAR expression. Cancer Research. 73: 863-863. DOI: 10.1158/1538-7445.Am2013-863 |
0.535 |
|
| 2012 |
Dai M, Al-Odaini AA, Arakelian A, Rabbani SA, Ali S, Lebrun JJ. A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion. Breast Cancer Research : Bcr. 14: R127. PMID 22995475 DOI: 10.1186/Bcr3322 |
0.494 |
|
| 2011 |
Chik F, Szyf M, Rabbani SA. Role of epigenetics in cancer initiation and progression. Advances in Experimental Medicine and Biology. 720: 91-104. PMID 21901621 DOI: 10.1007/978-1-4614-0254-1_8 |
0.445 |
|
| 2011 |
Rastelli L, Valentino ML, Minderman MC, Landin J, Malyankar UM, Lescoe MK, Kitson R, Brunson K, Souan L, Forenza S, Goldfarb RH, Rabbani SA. A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo. International Journal of Oncology. 39: 401-8. PMID 21567086 DOI: 10.3892/Ijo.2011.1040 |
0.478 |
|
| 2011 |
Harfouche R, Echavarria R, Rabbani SA, Arakelian A, Hussein MA, Hussain SN. Estradiol-dependent regulation of angiopoietin expression in breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 123: 17-24. PMID 20937382 DOI: 10.1016/J.Jsbmb.2010.09.005 |
0.499 |
|
| 2010 |
Rabbani SA, Ateeq B, Arakelian A, Valentino ML, Shaw DE, Dauffenbach LM, Kerfoot CA, Mazar AP. An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo Neoplasia. 12: 778-788. PMID 20927316 DOI: 10.1593/Neo.10296 |
0.517 |
|
| 2010 |
Rabbani SA, Valentino ML, Arakelian A, Ali S, Boschelli F. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Molecular Cancer Therapeutics. 9: 1147-57. PMID 20423991 DOI: 10.1158/1535-7163.Mct-09-0962 |
0.526 |
|
| 2010 |
Stefanska B, Bhattacharyya B, Han ZG, Huang J, Suderman M, Hallett M, Rabbani SA, Szyf M. Abstract 158: The landscape of DNA hypomethylation in liver cancer, its correlation with other cancers, and its potential role in cancer Cancer Research. 70: 158-158. DOI: 10.1158/1538-7445.Am10-158 |
0.468 |
|
| 2009 |
Devy L, Huang L, Naa L, Yanamandra N, Pieters H, Frans N, Chang E, Tao Q, Vanhove M, Lejeune A, van Gool R, Sexton DJ, Kuang G, Rank D, Hogan S, ... ... Rabbani SA, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Research. 69: 1517-26. PMID 19208838 DOI: 10.1158/0008-5472.Can-08-3255 |
0.439 |
|
| 2008 |
Ateeq B, Unterberger A, Szyf M, Rabbani SA. Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia (New York, N.Y.). 10: 266-78. PMID 18320071 DOI: 10.1593/Neo.07947 |
0.541 |
|
| 2008 |
Chen L, Maures TJ, Jin H, Huo JS, Rabbani SA, Schwartz J, Carter-Su C. SH2B1beta (SH2-Bbeta) enhances expression of a subset of nerve growth factor-regulated genes important for neuronal differentiation including genes encoding urokinase plasminogen activator receptor and matrix metalloproteinase 3/10. Molecular Endocrinology (Baltimore, Md.). 22: 454-76. PMID 17947375 DOI: 10.1210/Me.2007-0384 |
0.344 |
|
| 2007 |
Devy L, Rabbani SA, Stochl M, Ruskowski M, Mackie I, Naa L, Toews M, van Gool R, Chen J, Ley A, Ladner RC, Dransfield DT, Henderikx P. PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor. Neoplasia (New York, N.Y.). 9: 927-37. PMID 18030361 DOI: 10.1593/Neo.07544 |
0.465 |
|
| 2007 |
Garde SV, Forté AJ, Ge M, Lepekhin EA, Panchal CJ, Rabbani SA, Wu JJ. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anti-Cancer Drugs. 18: 1189-200. PMID 17893520 DOI: 10.1097/Cad.0B013E3282A213Ce |
0.456 |
|
| 2007 |
Rabbani SA, Mazar AP. Evaluating distant metastases in breast cancer: from biology to outcomes. Cancer Metastasis Reviews. 26: 663-74. PMID 17823779 DOI: 10.1007/S10555-007-9085-8 |
0.428 |
|
| 2007 |
Casimiro M, Rodriguez O, Pootrakul L, Aventian M, Lushina N, Cromelin C, Ferzli G, Johnson K, Fricke S, Diba F, Kallakury B, Ohanyerenwa C, Chen M, Ostrowski M, Hung MC, ... Rabbani SA, et al. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo. Cancer Research. 67: 4364-72. PMID 17483350 DOI: 10.1158/0008-5472.Can-06-1898 |
0.442 |
|
| 2007 |
Garde S, Fraser JE, Nematpoor N, Pollex R, Morin C, Forté A, Rabbani S, Panchal C, Gupta MB. Cloning, expression, purification and functional characterization of recombinant human PSP94. Protein Expression and Purification. 54: 193-203. PMID 17468008 DOI: 10.1016/J.Pep.2007.03.008 |
0.379 |
|
| 2007 |
Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Research. 67: 1580-8. PMID 17308097 DOI: 10.1158/0008-5472.Can-06-2027 |
0.554 |
|
| 2007 |
Harfouche R, Hussain SN, Rabbani SA, Sengupta S. Regulation of breast cancer extravasation by Angiopoietin‐1 The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A254-B |
0.402 |
|
| 2006 |
Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, Doñate F, Shaw DE, Mazar AP, Rabbani SA. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Molecular Cancer Therapeutics. 5: 2271-80. PMID 16985061 DOI: 10.1158/1535-7163.Mct-06-0100 |
0.519 |
|
| 2006 |
Shukeir N, Pakneshan P, Chen G, Szyf M, Rabbani SA. Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Research. 66: 9202-10. PMID 16982764 DOI: 10.1158/0008-5472.Can-06-1954 |
0.576 |
|
| 2006 |
Annabi B, Currie JC, Bouzeghrane M, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R. Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface binding. Biochemical and Biophysical Research Communications. 346: 358-66. PMID 16759641 DOI: 10.1016/J.Bbrc.2006.05.139 |
0.377 |
|
| 2006 |
Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer. 107: 289-98. PMID 16752412 DOI: 10.1002/Cncr.21978 |
0.418 |
|
| 2006 |
Annabi B, Bouzeghrane M, Currie JC, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R. Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling. Anti-Cancer Drugs. 17: 429-38. PMID 16550001 DOI: 10.1097/01.Cad.0000203388.68034.06 |
0.423 |
|
| 2006 |
Lamy S, Ruiz MT, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ, Annabi B. A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: implication in tumor angiogenesis. International Journal of Cancer. Journal International Du Cancer. 118: 2350-8. PMID 16331603 DOI: 10.1002/Ijc.21615 |
0.495 |
|
| 2005 |
Daigneault L, Panchal C, Scher HI, Slovin SF, Rabbani S, Dulude H, Garde S, Ruiz M, Wu J, Hawkins R. A synthetic peptide, PCK3145, for the treatment of hormone refractory prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4654. PMID 27947036 DOI: 10.1200/jco.2005.23.16_suppl.4654 |
0.354 |
|
| 2005 |
Pakneshan P, Szyf M, Rabbani SA. Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications. Current Cancer Drug Targets. 5: 471-88. PMID 16305345 DOI: 10.2174/156800905774574011 |
0.55 |
|
| 2005 |
Annabi B, Bouzeghrane M, Currie JC, Hawkins R, Dulude H, Daigneault L, Ruiz M, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R. A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis. Clinical & Experimental Metastasis. 22: 429-39. PMID 16283486 DOI: 10.1007/S10585-005-2669-1 |
0.486 |
|
| 2005 |
Shukeir N, Garde S, Wu JJ, Panchal C, Rabbani SA. Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer. Anti-Cancer Drugs. 16: 1045-51. PMID 16222145 DOI: 10.1097/00001813-200511000-00002 |
0.522 |
|
| 2005 |
Khalili P, Arakelian A, Chen G, Singh G, Rabbani SA. Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer Oncogene. 24: 6657-6666. PMID 16091754 DOI: 10.1038/Sj.Onc.1208790 |
0.491 |
|
| 2005 |
Rabbani SA, Khalili P, Arakelian A, Pizzi H, Chen G, Goltzman D. Regulation of parathyroid hormone-related peptide by estradiol: Effect on tumor growth and metastasis in vitro and in vivo Endocrinology. 146: 2885-2894. PMID 15831570 DOI: 10.1210/En.2005-0062 |
0.514 |
|
| 2005 |
Pakneshan P, Szyf M, Rabbani SA. Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells. Carcinogenesis. 26: 557-64. PMID 15618232 DOI: 10.1093/Carcin/Bgi009 |
0.446 |
|
| 2004 |
Szyf M, Pakneshan P, Rabbani SA. DNA methylation and breast cancer. Biochemical Pharmacology. 68: 1187-97. PMID 15313416 DOI: 10.1016/J.Bcp.2004.04.030 |
0.464 |
|
| 2004 |
Shukeir N, Arakelian A, Chen G, Garde S, Ruiz M, Panchal C, Rabbani SA. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia Cancer Research. 64: 5370-5377. PMID 15289344 DOI: 10.1158/0008-5472.Can-04-0788 |
0.527 |
|
| 2004 |
Szyf M, Pakneshan P, Rabbani SA. DNA demethylation and cancer: therapeutic implications. Cancer Letters. 211: 133-43. PMID 15219937 DOI: 10.1016/J.Canlet.2004.04.009 |
0.404 |
|
| 2004 |
Pakneshan P, Szyf M, Farias-Eisner R, Rabbani SA. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. The Journal of Biological Chemistry. 279: 31735-44. PMID 15150277 DOI: 10.1074/Jbc.M401669200 |
0.571 |
|
| 2004 |
Pakneshan P, Têtu B, Rabbani SA. Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3035-41. PMID 15131040 DOI: 10.1158/1078-0432.Ccr-03-0545 |
0.425 |
|
| 2003 |
Pakneshan P, Xing RH, Rabbani SA. Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 17: 1081-8. PMID 12773490 DOI: 10.1096/Fj.02-0973Com |
0.538 |
|
| 2003 |
Shukeir N, Arakelian A, Kadhim S, Garde S, Rabbani SA. Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in Vivo model of prostate cancer Cancer Research. 63: 2072-2078. PMID 12727822 |
0.417 |
|
| 2003 |
Pizzi H, Gladu J, Carpio L, Miao D, Goltzman D, Rabbani SA. Androgen regulation of parathyroid hormone-related peptide production in human prostate cancer cells. Endocrinology. 144: 858-67. PMID 12586762 DOI: 10.1210/En.2002-220754 |
0.475 |
|
| 2002 |
Guo Y, Pakneshan P, Gladu J, Slack A, Szyf M, Rabbani SA. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. The Journal of Biological Chemistry. 277: 41571-9. PMID 12198113 DOI: 10.1074/Jbc.M201864200 |
0.753 |
|
| 2002 |
Guo Y, Mazar AP, Lebrun JJ, Rabbani SA. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Research. 62: 4678-84. PMID 12183425 |
0.751 |
|
| 2002 |
Rabbani SA, Gladu J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Research. 62: 2390-7. PMID 11956102 |
0.435 |
|
| 2002 |
Hotte SJ, Hirte HW, Rabbani SA, Carling T, Hendy GN, Major PP. Hypercalcemia of Malignancy American Journal of Cancer. 1: 179-187. DOI: 10.2165/00024669-200201030-00003 |
0.31 |
|
| 2001 |
Carpio L, Gladu J, Goltzman D, Rabbani SA. Induction of osteoblast differentiation indexes by PTHrP in MG-63 cells involves multiple signaling pathways. American Journal of Physiology. Endocrinology and Metabolism. 281: E489-99. PMID 11500304 DOI: 10.1152/Ajpendo.2001.281.3.E489 |
0.324 |
|
| 2001 |
Degryse B, Orlando S, Resnati M, Rabbani SA, Blasi F. Urokinase/urokinase receptor and vitronectin/alpha(v)beta(3) integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways. Oncogene. 20: 2032-43. PMID 11360187 DOI: 10.1038/Sj.Onc.1204261 |
0.324 |
|
| 2001 |
Farias-Eisner R, Vician L, Reddy S, Basconcillo R, Rabbani SA, Wu YY, Bradshaw RA, Herschman HR. Expression of the urokinase plasminogen activator receptor is transiently required during "priming" of PC12 cells in nerve growth factor-directed cellular differentiation. Journal of Neuroscience Research. 63: 341-6. PMID 11170184 DOI: 10.1002/1097-4547(20010215)63:4<341::Aid-Jnr1028>3.0.Co;2-P |
0.33 |
|
| 2001 |
Rabbani SA, Mazar AP. The Role of the Plasminogen Activation System in Angiogenesis and Metastasis Surgical Oncology Clinics of North America. 10: 393-415. DOI: 10.1016/S1055-3207(18)30072-3 |
0.395 |
|
| 2000 |
Weber MH, Goltzman D, Kostenuik P, Rabbani S, Singh G, Orr FW. Mechanisms of tumor metastasis to bone. Critical Reviews in Eukaryotic Gene Expression. 10: 281-302. PMID 11272470 DOI: 10.1615/Critreveukargeneexpr.V10.I3-4.60 |
0.354 |
|
| 2000 |
Guo Y, Higazi AA, Arakelian A, Sachais BS, Cines D, Goldfarb RH, Jones TR, Kwaan H, Mazar AP, Rabbani SA. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 14: 1400-10. PMID 10877833 DOI: 10.1096/Fasebj.14.10.1400 |
0.772 |
|
| 2000 |
Rabbani SA, Harakidas P, Guo Y, Steinman D, Davidsen SK, Morgan DW. Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo. International Journal of Cancer. 87: 276-82. PMID 10861487 DOI: 10.1002/1097-0215(20000715)87:2<276::Aid-Ijc20>3.0.Co;2-L |
0.763 |
|
| 2000 |
Farias-Eisner R, Vician L, Silver A, Reddy S, Rabbani SA, Herschman HR. The urokinase plasminogen activator receptor (UPAR) is preferentially induced by nerve growth factor in PC12 pheochromocytoma cells and is required for NGF-driven differentiation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 230-9. PMID 10627600 DOI: 10.1523/Jneurosci.20-01-00230.2000 |
0.323 |
|
| 2000 |
Rabbani SA. Molecular mechanism of action of parathyroid hormone related peptide in hypercalcemia of malignancy: therapeutic strategies (review). International Journal of Oncology. 16: 197-206. PMID 10601566 DOI: 10.3892/IJO.16.1.197 |
0.301 |
|
| 1999 |
Xing RH, Rabbani SA. Regulation of Urokinase Production by Androgens in Human Prostate Cancer Cells: Effect on Tumor Growth and Metastases in Vivo1. Endocrinology. 140: 4056-4064. PMID 28200944 DOI: 10.1210/Endo.140.9.6946 |
0.487 |
|
| 1999 |
Xing RH, Rabbani SA. Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation. International Journal of Cancer. 81: 443-50. PMID 10209960 DOI: 10.1002/(Sici)1097-0215(19990505)81:3<443::Aid-Ijc19>3.0.Co;2-T |
0.537 |
|
| 1999 |
Rabbani SA, Gladu J, Harakidas P, Jamison B, Goltzman D. Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo. International Journal of Cancer. 80: 257-64. PMID 9935208 DOI: 10.1002/(Sici)1097-0215(19990118)80:2<257::Aid-Ijc15>3.0.Co;2-3 |
0.459 |
|
| 1999 |
Degryse B, Resnati M, Rabbani SA, Villa A, Fazioli F, Blasi F. Src-Dependence and Pertussis-Toxin Sensitivity of Urokinase Receptor-Dependent Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells Blood. 94: 649-662. DOI: 10.1182/Blood.V94.2.649.414K34_649_662 |
0.32 |
|
| 1998 |
Rabbani SA, Xing RH. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. International Journal of Oncology. 12: 911-20. PMID 9499455 DOI: 10.3892/Ijo.12.4.911 |
0.573 |
|
| 1997 |
Rabbani SA, Gladu J, Mazar AP, Henkin J, Goltzman D. Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase. Journal of Cellular Physiology. 172: 137-45. PMID 9258335 DOI: 10.1002/(Sici)1097-4652(199708)172:2<137::Aid-Jcp1>3.0.Co;2-P |
0.401 |
|
| 1997 |
Rabbani SA, Harakidas P, Gladu J, Srivastava S, Diarra A, Sauvé R, Karaplis AC, Henderson JE, Goltzman D, Hendy GN. Expression and characterization of recombinant rat parathyroid hormone-related peptide (1-141) and an amino-terminally-truncated analogue (38-141) Molecular and Cellular Endocrinology. 130: 13-21. PMID 9220017 DOI: 10.1016/S0303-7207(97)00068-3 |
0.301 |
|
| 1997 |
Li M, Karakji EG, Xing R, Fryer JN, Carnegie JA, Rabbani SA, Tsang BK. Expression of urokinase-type plasminogen activator and its receptor during ovarian follicular development. Endocrinology. 138: 2790-9. PMID 9202219 DOI: 10.1210/Endo.138.7.5221 |
0.375 |
|
| 1997 |
Xing R, Rabbani SA. 24 Transcriptional regulation of urokinase (uPA) gene expression in hormone dependent malignancies Fibrinolysis and Proteolysis. 11: 7. DOI: 10.1016/S0268-9499(97)80139-7 |
0.314 |
|
| 1996 |
Aklilu F, Park M, Goltzman D, Rabbani SA. Increased PTHRP production by a tyrosine kinase oncogene, Tpr-Met: role of the Ras signaling pathway. The American Journal of Physiology. 271: E277-83. PMID 8770021 DOI: 10.1152/Ajpendo.1996.271.2.E277 |
0.351 |
|
| 1996 |
Xing RH, Rabbani SA. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. International Journal of Cancer. 67: 423-9. PMID 8707419 DOI: 10.1002/(Sici)1097-0215(19960729)67:3<423::Aid-Ijc18>3.0.Co;2-8 |
0.544 |
|
| 1995 |
Rabbani SA, Harakidas P, Davidson DJ, Henkin J, Mazar AP. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). International Journal of Cancer. Journal International Du Cancer. 63: 840-5. PMID 8847143 DOI: 10.1002/Ijc.2910630615 |
0.54 |
|
| 1995 |
Liu B, Amizuka N, Goltzman D, Rabbani SA. Inhibition of processing of parathyroid hormone-related peptide by anti-sense furin: effect in vitro and in vivo on rat Leydig (H-500) tumor cells. International Journal of Cancer. 63: 276-81. PMID 7591217 DOI: 10.1002/Ijc.2910630222 |
0.502 |
|
| 1995 |
Rabbani SA, Gladu J, Liu B, Goltzman D. Regulation in vivo of the growth of Leydig cell tumors by antisense ribonucleic acid for parathyroid hormone-related peptide. Endocrinology. 136: 5416-22. PMID 7588290 DOI: 10.1210/Endo.136.12.7588290 |
0.486 |
|
| 1995 |
Liu DF, Rabbani SA. Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC-3. The Prostate. 27: 269-76. PMID 7479394 DOI: 10.1002/Pros.2990270506 |
0.516 |
|
| 1994 |
Rabbani SA, Rajwans N, Achbarou A, Murthy KK, Goltzman D. Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts. Febs Letters. 338: 69-74. PMID 8307160 DOI: 10.1016/0014-5793(94)80118-5 |
0.335 |
|
| 1993 |
Haq M, Kremer R, Goltzman D, Rabbani SA. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo Journal of Clinical Investigation. 91: 2416-2422. PMID 8514854 DOI: 10.1172/Jci116475 |
0.364 |
|
| 1993 |
Rabbani SA, Haq M, Goltzman D. Biosynthesis and processing of endogenous parathyroid hormone related peptide (PTHRP) by rat Leydig cell tumor H-500 Biochemistry. 32: 4931-4937. PMID 8490029 DOI: 10.1021/Bi00069A030 |
0.313 |
|
| 1993 |
Liu B, Goltzman D, Rabbani SA. Regulation of parathyroid hormone-related peptide production in vitro by the rat hypercalcemic Leydig cell tumor H-500. Endocrinology. 132: 1658-64. PMID 8462465 DOI: 10.1210/Endo.132.4.8462465 |
0.452 |
|
| 1993 |
Rabbani SA, Yasuda T, Bennett HP, Hendy GN, Banville D. Nucleotide and (derived) amino acid sequence of a novel peptide from a rat (hypercalcemic) Leydig cell tumor. Biochimica Et Biophysica Acta. 1171: 229-30. PMID 1482688 DOI: 10.1016/0167-4781(92)90128-M |
0.361 |
|
| 1993 |
Goltzman D, Bolivar I, Rabbani SA. Studies on the pathogenesis of osteoblastic metastases by prostate cancer. Advances in Experimental Medicine and Biology. 324: 165-71. PMID 1283497 DOI: 10.1007/978-1-4615-3398-6_17 |
0.455 |
|
| 1992 |
Goltzman D, Bolivar I, Moroz L, Rabbani S. Urokinase and the mechanism of osteoblastic metastases by prostate cancer Fibrinolysis. 6: 63-69. DOI: 10.1016/0268-9499(92)90096-Z |
0.431 |
|
| 1991 |
Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Henkin J, Goltzman D. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochemical and Biophysical Research Communications. 173: 1058-64. PMID 2125213 DOI: 10.1016/S0006-291X(05)80893-9 |
0.303 |
|
| 1990 |
Henderson JE, Shustik C, Kremer R, Rabbani SA, Hendy GN, Goltzman D. Circulating concentrations of parathyroid hormone-like peptide in malignancy and in hyperparathyroidism Journal of Bone and Mineral Research. 5: 105-113. PMID 2316398 DOI: 10.1002/Jbmr.5650050203 |
0.378 |
|
| 1990 |
Rabbani SA, Kaiser SM, Henderson JE, Bernier SM, Mouland AJ, Roy DR, Zahab DM, Sung WL, Goltzman D, Hendy GN. Synthesis and characterization of extended and deleted recombinant analogues of parathyroid hormone-(1-84): correlation of peptide structure with function. Biochemistry. 29: 10080-9. PMID 2176861 DOI: 10.1021/Bi00495A010 |
0.326 |
|
| 1989 |
Yasuda T, Banville D, Rabbani SA, Hendy GN, Goltzman D. Rat parathyroid hormone-like peptide: comparison with the human homologue and expression in malignant and normal tissue. Molecular Endocrinology (Baltimore, Md.). 3: 518-25. PMID 2747658 DOI: 10.1210/Mend-3-3-518 |
0.35 |
|
| 1987 |
Koutsilieris M, Rabbani SA, Bennett HP, Goltzman D. Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. The Journal of Clinical Investigation. 80: 941-6. PMID 2443538 DOI: 10.1172/Jci113186 |
0.389 |
|
| 1986 |
Rabbani SA, Mitchell J, Roy DR, Kremer R, Bennett HP, Goltzman D. Purification of peptides with parathyroid hormone-like bioactivity from human and rat malignancies associated with hypercalcemia. Endocrinology. 118: 1200-10. PMID 3948772 DOI: 10.1210/Endo-118-3-1200 |
0.425 |
|
| 1986 |
Goltzman D, Bennett HP, Koutsilieris M, Mitchell J, Rabbani SA, Rouleau MF. Studies of the multiple molecular forms of bioactive parathyroid hormone and parathyroid hormone-like substances. Recent Progress in Hormone Research. 42: 665-703. PMID 3016836 DOI: 10.1016/B978-0-12-571142-5.50020-3 |
0.302 |
|
| 1986 |
Koutsilieris M, Rabbani SA, Goltzman D. Selective osteoblast mitogens can be extracted from prostatic tissue. The Prostate. 9: 109-15. PMID 2428019 DOI: 10.1002/Pros.2990090202 |
0.345 |
|
| Show low-probability matches. |